The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
about
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age GroupsAllogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsThe evolving treatment paradigm in myelofibrosisThe indications for allogeneic stem cell transplantation in myeloid malignancies.Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCTMPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisRole of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisJAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.Advances in myelofibrosis: a clinical case approach.Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.Allogeneic stem cell transplantation for myelofibrosis in 2012.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Myelofibrosis: an update on current pharmacotherapy and future directions.Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesAn update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Current Challenges in Stem Cell Transplantation in Myelofibrosis.Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Prognosis of Primary Myelofibrosis in the Genomic EraManagement of myelofibrosis: JAK inhibition and beyond.Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.Emerging therapeutic options for myelofibrosis: a Canadian perspective.Will JAK1/2 inhibitors change the standard of care for myelofibrosis?Mutations and prognosis in primary myelofibrosis.Benefits and pitfalls of Peg-Interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis, a French Intergroup of Myeloproliferative neoplasms (FIM) study.Guideline for the diagnosis and management of myelofibrosis.Novel Therapies for Myelofibrosis.Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
P2860
Q26786893-212FFCC1-4953-4EFE-8E10-C4A5B0CD79D2Q26863610-99671357-5E01-482C-A957-9E8DD9A923D8Q27021968-CF68F1D2-BEBE-4E38-A774-F5F5A4F824ECQ30316611-E57A4E8C-C775-4432-83FE-7D8B54948FFDQ33556843-1FC38176-6513-4DFE-9DCF-2905CB017703Q34047897-1A75F179-87F9-4420-83E3-C7143627D6CAQ34625390-B6109DEB-1135-433A-8DD0-6CB019C7856CQ35634902-1F664304-D324-4E1B-8A3C-72CD0526AFCCQ35735663-385C68CB-93FA-4A1D-BD17-9E999264F841Q36805838-25E72568-2C35-4ABE-9A93-C2E21CD8740CQ37212674-440D9C89-04B5-45B2-8F72-B1DF53AF6881Q37457111-A1E69449-E209-4974-B20E-2E548FB90187Q37998567-575430C6-9782-4F13-8EE2-D59580C080BBQ38014534-E22F99CC-19B7-42C7-84C8-5D4F9CDA2D89Q38018908-27B8BC03-2320-450A-BCFE-664EF9870667Q38091447-24C19BE1-35A7-4DA9-9FE1-AE3EB1A6F858Q38174781-28469F7F-1131-46AA-8978-6B2652968EE7Q38193610-854F0DF1-556F-4DAA-8224-F8DA7201CC54Q38236642-7262C550-CF16-4804-9D8B-B75755985C59Q38349213-9ADB1C5F-1D3F-4F0F-86A7-1D67B951C5FDQ38569146-94A404E1-CC02-45F7-9712-4F73E2D52D88Q38570614-9DBDA3A3-B1EF-48E2-B563-001EA9BC0435Q38603384-84F1EA9A-79E5-4A69-A523-F487624249B3Q38926804-C8386532-211F-4F3C-99AC-D655484CA4F9Q39232415-23D0B0EE-F198-4883-BB0C-00F9262DC43CQ39482201-8DA5B876-956A-4DA7-BFA9-2709EDCC2547Q40261233-A00B8115-D9C8-4CF2-A9DB-F5E01C0260B4Q40453557-9B514762-D275-445D-84DE-3EBC7EC2E185Q41625749-CA6F71C9-4323-4A55-B862-F9973BD5E961Q41627599-BB9DBCA0-419C-4FA5-8770-B2EBADABE5FBQ42552033-FF2BAFC9-D1C7-4A68-8AE7-BE1DAF00522DQ44429606-C71EEC84-E140-45DA-A1E4-245A918D7336Q50020976-1A4B306B-13AF-47CE-926A-ADD833C409B9Q50495964-E1E07099-657D-4CA8-8D00-CA4DF0BC12A7Q52817185-C07BF182-6476-4D08-A6DA-4AD3C0B15127Q53099028-7335A967-E6A2-48A9-A48E-1CCB82FBB613
P2860
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The Dynamic International Prog ...... opoietic cell transplantation.
@ast
The Dynamic International Prog ...... opoietic cell transplantation.
@en
type
label
The Dynamic International Prog ...... opoietic cell transplantation.
@ast
The Dynamic International Prog ...... opoietic cell transplantation.
@en
prefLabel
The Dynamic International Prog ...... opoietic cell transplantation.
@ast
The Dynamic International Prog ...... opoietic cell transplantation.
@en
P2093
P2860
P50
P1433
P1476
The Dynamic International Prog ...... opoietic cell transplantation.
@en
P2093
Andrew R Rezvani
Bart L Scott
David Myerson
Jerald P Radich
Jonathan Grim
Michael L Linenberger
Mohamed L Sorror
Ted A Gooley
Veronika Buxhofer-Ausch
P2860
P304
P356
10.1182/BLOOD-2011-08-372904
P407
P577
2012-01-10T00:00:00Z